SAN DIEGO, Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief ExecutiveOfficer, will present at the BIO CEO & Investor Conference on Thursday,February 24, 2005, at 2:30 pm Eastern Time at the Waldorf=Astoria Hotel in NewYork City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors section and anarchived recording will be available on the website through March 10, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has four drug programsin clinical development as well as a portfolio of preclinical and discoveryassets directed at large unmet medical needs, including schizophrenia,Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietarydrug discovery platform, ACADIA has discovered all of the drug candidates inits product pipeline. ACADIA's corporate headquarters and biology researchfacilities are located in San Diego, California and its chemistry researchfacilities are located near Copenhagen, Denmark.
For further information, please contact Lisa Barthelemy, Director ofInvestor Relations, or Thomas H. Aasen, Vice President and Chief FinancialOfficer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871,ir@acadia-pharm.com.
Lisa Barthelemy, Director of Investor Relations, or Thomas H. Aasen, Vice Presidentand Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871,ir@acadia-pharm.com